Core Insights - Yinosh's stock increased by 2.46% on September 25, with a trading volume of 107 million yuan [1] - The company reported a financing net purchase of 2.2852 million yuan on the same day, with a total financing balance of 75.0274 million yuan, representing 1.67% of its market capitalization [1] - Yinosh's main business involves providing non-clinical research services in the biopharmaceutical sector, with 96.31% of its revenue coming from non-clinical services [1] Financial Performance - As of June 30, Yinosh's revenue for the first half of 2025 was 375 million yuan, a year-on-year decrease of 38.04% [2] - The company reported a net profit attributable to shareholders of -15.1895 million yuan, a significant decline of 115.88% compared to the previous period [2] Shareholder and Institutional Holdings - As of June 30, the number of Yinosh's shareholders was 5,386, a decrease of 0.90% from the previous period [2] - The top ten circulating shareholders include ICBC Medical Health Stock, which increased its holdings by 72,300 shares, and two new shareholders, namely ICBC Strategic Transformation Stock and Harvest Medical Health Stock [3]
益诺思9月25日获融资买入1081.18万元，融资余额7502.74万元